@callysays @rothys I just experienced the same thing! I’ve never experienced anything this bad in my life. I have spent a lot of money at this place but I am done as this is a shady operation
@rothys I just had the most undesirable customer service experience in my life. It will lead me to never order another item from you again. I’m not even sure what that means and was never told “all sales final”.
@grok@TheBuckeyeNut I hate Ohio State a lot and have a lot of respect for Miami but given that I watch all the buckeyes games because I hate them so much, I find it a bit ridiculous.
🎆 Humana hosted an Investor Day in Louisville this past week (6/16), giving much-needed clarity on where they stand in 2025 and how they plan to drive value in Medicare Advantage (MA) over the next several years. After lighter content on recent earnings calls, this session offered deeper insights into their recovery plan, operational focus, and long-term strategy. Some good insights for UnitedHealth Group/UnitedHealthcare, CVS Health/Aetna, a CVS Health Company, Centene Corporation/Wellcare Medicare and Elevance Health as we head into Q2 earnings next month.
📈 The market liked what it heard which is a clear, disciplined path forward for new CEO Jim Rechtin. The stock initially jumped 5% after the event and finished up 3% for the week.
🗞️ In my latest Substack, I break down what I see as the most important themes for me beyond the headlines.
Here are 6 key takeaways:
🌠 A shift from STAR dependency — Humana acknowledged its over-reliance on STAR ratings in past strategies and is now focused on drivers it can control: clinical outcomes, operating leverage, member experience, and disciplined capital deployment.
🖥️ V28 changes reshape growth strategy — The move from ICD-9 to ICD-10 coding under V28 limits code stacking, forcing a pivot toward building longer-term member relationships/engagement to improve outcomes and margin .
👵 MA remains attractive despite near-term headwinds — Humana reinforced the value proposition of MA: better outcomes, lower costs for members, bipartisan support, and structural growth from senior demographics.
🏥 CenterWell’s growing role — Pharmacy, primary care, and home health are increasingly integrated to drive outcomes, lower cost of care, and unlock enterprise margin potential (2-4x greater margin on members using multiple CenterWell Home Health, CenterWell Senior Primary Care, CenterWell Pharmacy services).
🤖 AI and tech enablement as margin drivers — Investments in omni-channel experiences, automation, ambient listening, and Agentic AI aim to deliver 150-180 bps of operating leverage by 2028.
🙃 2026 will be tough, but the long-term plan is in place — They’ve priced 2026 bids conservatively and are focusing on margin recovery, MA retention, Medicaid J-curve progression, and positioning CenterWell as a key growth engine.
Look forward to UnitedHealth Group kicking off the Q2 earnings in a couple of weeks! $hum $elv $cnc $ci $cvs $unh
https://t.co/PTHI4N8Y7V
Hospitals, payors, AI, and the investment shifts shaping 2025 - what’s real and what’s hype?
@jeffdelverne, @GrantHesser, Eric Epstein, and Drew Wozniak are breaking it down at Pulse Check, and we’d love to have you there.
Register here to save your spot👇
https://t.co/wPl6tWB4EI
I was able to dig a bit deeper into the @UnitedHealthGrp worst trading day since 1998 but is the selloff justified?
UnitedHealth Group just reported on Thursday and then followed with a 22% stock drop, following a guidance cut for both EPS and revenue for 2025. This marks the company’s worst trading day since 1998, but the question remains — is this an overreaction or a sign of deeper issues?
Below is my deeper dive after digging through the earnings transcript:
🔻 UnitedHealthcare Medicare Advantage saw double the expected utilization, leading to a Medical Care Ratio of 87.5% for 2025 (±50bps).
💡 OptumHealth Holdings, LLC struggled with underreported risk coding from inherited members, leading to unexpected headwinds in their value-based care model.
💊 OptumRx Holdings LLC had 14% revenue growth, with a standout 3% script growth and 80 drugs added to their non-PA formulary, signaling a shift toward more transparent PBM practices.
📊 Q2 will be a critical test for UnitedHealth Group, with expectations set for membership growth of 800,000 in Medicare Advantage alone.
Andrew Witty also highlighted a key factor: common procedures like heart surgeries in the U.S. are 4x more expensive than in Germany, Australia, or the UK, and this cost pressure is a major reason behind the challenges in their unit economics.
Despite the market volatility, UnitedHealth Group’s long-term prospects remain solid but there are some big hurdles to overcome in the near term.
💬 Want to dive deeper into what’s really going on behind the scenes? Check out my full breakdown of UnitedHealth Group’s Q1 2025 earnings.
https://t.co/3PoXF8TJrY